News

Neurology News Network for the week ending August 8, 2020.

The agent, marketed under the brand name Evrysdi, is the first at-home therapy indicated for treatment of adults and children with SMA.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 7, 2020.

Kathleen Digre, MD, past president of the American Headache Society, discusses the barriers to correct identification and treatment of eye symptoms in people with migraine.

The director of the Center for Neurological Restoration at Cleveland Clinic detailed the recent technological and therapeutic innovations and their advantages in treating Parkinson disease.

A PDUFA date has been scheduled for March 7, 2021, but the agency said it would consider an even more expedited review if warranted.

AUPN Leading Edge Episode 1 features Clifton L. Gooch, MD, who discusses this new podcast series from AUPN. [LISTEN TIME: 1 minute]

Marinus Pharmaceuticals, the agent’s manufacturer, plans to announce topline data from the phase 3 Marigold study in the third quarter of this year.

Katrina Celis, MD, a postdoctoral fellow at the University of Miami Miller School of Medicine, discussed how ancestral genetics can play a key role in Alzheimer disease risk.

The investigators wrote that the Alzheimer’s Association “Part the Cloud” funded 24-week treatment trial is now warranted after sargramostim showed a safe and tolerable profile.

Through a joint initiative with Bill Gates, a $3.3 million funding influx will go toward the Strategically Focused Research Network on Health Technologies and Innovation program’s fifth network center.

The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center discussed the history of the research and offered insight into the attempt to regenerate injured tissue in the brain.

The co-director of the Neurological Clinical Research Institute at Massachusetts General Hospital spoke to the need for more collaborative efforts in ALS research.

Data from 2 posters presented at AAIC 2020 suggest that there is an unmet need for safe and effective treatments for patients who experience dementia-related psychosis.

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center detailed the phase 2 study findings of nilotinib in patients with Alzheimer disease.

An overview of the tweet chat on mental health in neurological disorders, featuring highlighted contributions from the medical community.

The findings suggest that plasma exchange has the potential to offer patients with Alzheimer disease a new modality of treatment, though additional studies are needed to further investigate the current areas of uncertainty.

Results from the ATLAS Posterior PMA trial demonstrated that physicians can now address the more difficult posterior circulation aneurysms, offering hope for better outcomes in that patient population.

Excessive alcohol intake, head injury, and air pollution are among the newest dementia risk factors added to the Lancet Commission report.

The approval also expands the age range of all Epidiolex indications to include patients age 1 and older.

NeuroPace’s FDA-approved neurostimulation device helped 35% of patients with epilepsy achieve ≥90% reduction in seizure frequency, with 18% of patients reporting seizure freedom at last follow-up.

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center details his findings from the phase 2 study of nilotinib in patients with Alzheimer disease.

The postdoctoral fellow at the University of Miami Miller School of Medicine detailed her study presented at AAIC 2020 that examined Alzheimer risk associated with APOE ε4 in different genetic populations.

Neurology News Network for the week ending August 1, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 31, 2020.

The gepant agent significantly reduced mean monthly migraine days across all 3 doses—10 mg, 30 mg, and 60 mg—compared with placebo over the 12-week treatment period.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jeffrey Cummings, MD, ScD.

Multiple studies presented at AAIC 2020 highlight and confirm previous hypotheses of the role that early life cardiovascular risk factors play for individuals who develop late life dementia.

The co-director of the Neurological Clinical Research Institute at Massachusetts General Hospital discussed how the investigational agent might fit into the landscape of amyotrophic lateral sclerosis treatment as it progresses through the pipeline.

The data suggests that a planned multiple ascending dose study and a phase 2a proof-of-concept study in patients with mild cognitive impairment could be on the way.